Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2015, Article ID 163952, 5 pages
http://dx.doi.org/10.1155/2015/163952
Case Report

Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still’s Disease

1Department of General Internal Medicine and Rheumatology, Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8562, Japan
2Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8562, Japan
3Department of Hematology, Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8562, Japan
4Department of Pathology, Nagasaki Medical Center, Kubara 2-1001-1, Omura 856-8562, Japan
5Department of Rheumatology, Nagasaki University Hospital, Nagasaki 852-8121, Japan

Received 4 November 2015; Revised 4 December 2015; Accepted 8 December 2015

Academic Editor: Jamal Mikdashi

Copyright © 2015 Yoshika Tsuji et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Gerfaud-Valentin, Y. Jamilloux, J. Iwaz, and P. Sève, “Adult-onset Still's disease,” Autoimmunity Reviews, vol. 13, no. 7, pp. 708–722, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Fautrel, E. Zing, J.-L. Golmard et al., “Proposal for a new set of classification criteria for adult-onset still disease,” Medicine, vol. 81, no. 3, pp. 194–200, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. I. A. Al-Homood, “Biologic treatments for adult-onset still's disease,” Rheumatology, vol. 53, no. 1, pp. 32–38, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Nakahara, T. Mima, N. Yoshio-Hoshino, M. Matsushita, J. Hashimoto, and N. Nishimoto, “A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years,” Modern Rheumatology, vol. 19, no. 1, pp. 69–72, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Matsumoto, T. Nagashima, S. Takatori et al., “Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab,” Clinical Rheumatology, vol. 28, no. 4, pp. 485–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Dhote, J. Simon, T. Papo et al., “Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review,” Arthritis Care & Research, vol. 49, no. 5, pp. 633–639, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. L. K. Weaver and E. M. Behrens, “Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis,” Current Opinion in Rheumatology, vol. 26, no. 5, pp. 562–569, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. G. S. Schulert and A. A. Grom, “Macrophage activation syndrome and cytokine-directed therapies,” Best Practice and Research: Clinical Rheumatology, vol. 28, no. 2, pp. 277–292, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. N. K. Loh, M. Lucas, S. Fernandez, and D. Prentice, “Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra,” Internal Medicine Journal, vol. 42, no. 12, pp. 1358–1362, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Savage, T. Wazir, M. Drake, R. Cuthbert, and G. Wright, “Fulminant myocarditis and macrophage activation syndrome secondary to adult-onset Still's disease successfully treated with tocilizumab,” Rheumatology, vol. 53, no. 7, Article ID keu019, pp. 1352–1353, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Sandhu, A. Chesney, E. Piliotis, R. Buckstein, and S. Koren, “Macrophage activation syndrome after etanercept treatment,” Journal of Rheumatology, vol. 34, no. 1, pp. 241–242, 2007. View at Google Scholar · View at Scopus
  12. M. Yamaguchi, A. Ohta, T. Tsunematsu et al., “Preliminary criteria for classification of adult Still's disease,” Journal of Rheumatology, vol. 19, no. 3, pp. 424–430, 1992. View at Google Scholar · View at Scopus
  13. A. T. J. Maria, A. Le Quellec, C. Jorgensen, I. Touitou, S. Rivière, and P. Guilpain, “Adult onset still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions,” Autoimmunity Reviews, vol. 13, no. 11, pp. 1149–1159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. G. N. Usmani, B. A. Woda, and P. E. Newburger, “Advances in understanding the pathogenesis of HLH,” British Journal of Haematology, vol. 161, no. 5, pp. 609–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Minoia, S. Davì, A. Horne et al., “Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients,” Arthritis & Rheumatology, vol. 66, no. 11, pp. 3160–3169, 2014. View at Publisher · View at Google Scholar
  16. J. Pouchot and J.-B. Arlet, “Biological treatment in adult-onset Still's disease,” Best Practice and Research: Clinical Rheumatology, vol. 26, no. 4, pp. 477–487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Ortiz-Sanjuán, R. Blanco, L. Riancho-Zarrabeitia et al., “Efficacy of Anakinra in refractory adult-onset still's disease: multicenter study of 41 patients and literature review,” Medicine, vol. 94, no. 39, Article ID e1554, 2015. View at Publisher · View at Google Scholar
  18. F. Ortiz-Sanjuán, R. Blanco, V. Calvo-Rio et al., “Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients,” Arthritis & Rheumatology, vol. 66, no. 6, pp. 1659–1665, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Banse, O. Vittecoq, Y. Benhamou, M. Gauthier-Prieur, T. Lequerré, and H. Lévesque, “Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease,” Joint Bone Spine, vol. 80, no. 6, pp. 653–655, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Kobayashi, Y. Takahashi, H. Yamashita, H. Kaneko, and A. Mimori, “Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome,” Modern Rheumatology, vol. 21, no. 1, pp. 92–96, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Efthimiou and S. Georgy, “Pathogenesis and management of adult-onset Still's disease,” Seminars in Arthritis and Rheumatism, vol. 36, no. 3, pp. 144–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Efthimiou, P. K. Paik, and L. Bielory, “Diagnosis and management of adult onset Still's disease,” Annals of the Rheumatic Diseases, vol. 65, no. 5, pp. 564–572, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Kumakura and Y. Murakawa, “Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults,” Arthritis and Rheumatology, vol. 66, no. 8, pp. 2297–2307, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. J.-I. Henter, A. Horne, M. Aricó et al., “HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis,” Pediatric Blood and Cancer, vol. 48, no. 2, pp. 124–131, 2007. View at Publisher · View at Google Scholar · View at Scopus